SOURCE: IsoRay Inc.

January 12, 2015 08:15 ET

IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed on the NYSE Group

RICHLAND, WA--(Marketwired - Jan 12, 2015) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that it ranked 5th highest in share price performance for the 2014 calendar year, with a 192% increase, among all 2,417 listed companies on the NYSE Group, which includes the NYSE and the NYSE MKT.

IsoRay Chairman and CEO Dwight Babcock commented, "It is very rewarding to see the market begin to understand the tremendous potential benefits IsoRay and its products, utilizing IsoRay's patented isotope Cesium-131, can offer to pediatric and adult patients suffering the ravages of cancer located in the brain, head and neck, lung, gynecological and prostate. As institutional study results are being peer reviewed and published, evidence is growing as to how well Cesium-131 kills cancer and its ability to provide an improved quality of life. Other institutional studies continue to accrue patients or are allowing their data to mature to a point that will be eligible for submittal to peer review. Cesium-131 not only successfully treats primary cancers but also those cancers that recur when the current standard of care has failed." 

25 Best YTD Price Return on NYSE Group (12/31/2014) 
Rank Ticker Company Name Price Return YTD
1 JOB General Employment Enterprises, Inc. 465%
2 VRS Verso Corp 448%
3 RIC Richmont Mines Inc. 216%
4 HCHC HC2 Holdings, Inc. 196%
5 ISR IsoRay, Inc. 192%
6 IG IGI Laboratories, Inc. 189%
7 CTP CTPartners Executive Search Inc. 171%
8 BDR Blonder Tongue Laboratories, Inc. 169%
9 BBW BuildABear Workshop, Inc. 166%
10 CODE Spansion Inc. Class A 146%
11 HRT Arrhythmia Research Technology, Inc. 143%
12 VIPS Vipshop Holdings Ltd Sponsored ADR 134%
13 STRP Straight Path Communications, Inc. Class B 131%
14 BDL Flanigan's Enterprises, Inc. 126%
15 NEWM New Media Investment Group, Inc. 125%
16 LUV Southwest Airlines Co. 125%
17 MMI Marcus & Millichap, Inc. 123%
18 BITA Bitauto Holdings Ltd. Sponsored ADR 120%
19 PANW Palo Alto Networks, Inc. 113%
20 ROX Castle Brands Inc. 113%
21 AINC Ashford Inc 107%
22 IBIO iBio, Inc. 104%
23 KIQ Kelso Technologies Inc. 103%
24 BFR BBVA Banco Frances SA Sponsored ADR 98%
25 DPW Digital Power Corporation 96%

IsoRay CEO Dwight Babcock further commented, "We are extremely excited to see that our products -- Cesium-131 isotope seeds and our GliaSite® radiation balloon therapy system -- continue to perform so well against aggressive cancers throughout the body. As institutional data continues to accrue and mature with follow-up data, we believe the results will further confirm Cesium-131 can have a very favorable impact on local control, especially for cancers that have shown a tendency to recur at the site of surgery. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life. The message is clear and the medical community is increasingly being made aware of the innovative alternative our products offer for their cancer patients."

IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the tumor. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system. 

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement

Past market performance of IsoRay stock does not provide any indication of future performance. In addition, statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of our products will increase or continue, whether awareness of our products in the medical community will continue or increase, whether future and ongoing studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC.

Contact Information